← Back to Search

Device

CGM Use for Diabetes (REST Trial)

N/A
Recruiting
Research Sponsored by Joslin Diabetes Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Insulin treatment includes: ≥3 insulin injections/day or on insulin pump therapy
T1D or T2D with duration longer than 1 year
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months vs 12 months
Awards & highlights

REST Trial Summary

This trial is looking at whether or not the REST model can help older adults with type 1 or type 2 diabetes adopt and sustain continuous glucose monitoring (CGM). The REST model is a patient-centered model that focuses on providing resources and support to patients to help them manage their diabetes. The trial will also look at the impact of the REST model on economic factors and quality of life measures.

Who is the study for?
This trial is for older adults aged 65 or above with Type 1 or Type 2 Diabetes, who are on complex insulin regimens and have not used a Continuous Glucose Monitor (CGM) before or aren't meeting their glycemic goals. Participants must be willing to wear the CGM device at all times and use a smartphone for data upload.Check my eligibility
What is being tested?
The study tests the REST model's effectiveness in helping older adults adopt and keep using a CGM. It will also explore how this model affects quality of life and economic factors, aiming to create a sustainable framework for CGM use.See study design
What are the potential side effects?
While specific side effects are not mentioned, wearing a CGM may cause skin irritation where it attaches, potential allergic reactions to adhesive materials, or discomfort from carrying the device.

REST Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I take insulin more than 3 times a day or use an insulin pump.
Select...
I have had type 1 or type 2 diabetes for over a year.
Select...
My blood sugar often drops below 70 mg/dL or stays within 70-180 mg/dL less than 40% of the time.
Select...
I use or have never used a CGM but my blood sugar levels are not on target.
Select...
I am 65 years old or older.

REST Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months vs 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months vs 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The co-primary effectiveness outcomes
The co-primary implementation outcomes
Secondary outcome measures
Cost Effectivness
Cost effectivness
Diabetes health related quality of life measures
+3 more

REST Trial Design

1Treatment groups
Experimental Treatment
Group I: Single ArmExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Continuous Glucose Monitor
2021
Completed Early Phase 1
~860

Find a Location

Who is running the clinical trial?

State University of New York - Upstate Medical UniversityOTHER
172 Previous Clinical Trials
27,212 Total Patients Enrolled
2 Trials studying Diabetes
79 Patients Enrolled for Diabetes
Joslin Diabetes CenterLead Sponsor
96 Previous Clinical Trials
26,454 Total Patients Enrolled
11 Trials studying Diabetes
1,135 Patients Enrolled for Diabetes
Cecilia HealthUNKNOWN

Media Library

Continuous Glucose Monitor (Device) Clinical Trial Eligibility Overview. Trial Name: NCT05337826 — N/A
Diabetes Research Study Groups: Single Arm
Diabetes Clinical Trial 2023: Continuous Glucose Monitor Highlights & Side Effects. Trial Name: NCT05337826 — N/A
Continuous Glucose Monitor (Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05337826 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the major goals of this trial?

"This trial, which will span baseline to 6 months, has two primary implementation outcomes. Additionally, it aims to measure the amount of time spent in hypoglycemia (sensor glucose <70 mg/dL), visits needed for CGM use initiation and maintenance, as well as cost-effectiveness ratios compared with standard care."

Answered by AI

Is enrollment still available for this clinical trial?

"Affirmative. The clinicaltrials.gov portal states that this trial is actively seeking patients for enrollment, with the study being first posted on April 20th 2022 and recently updated on September 15th 2022. The research team seeks to recruit 120 participants from two distinct sites."

Answered by AI

What is the current population of participants in this research?

"Affirmative, clinicaltrials.gov data indicates that this investigation is actively seeking participants. It was initially listed on April 20th 2022 and the details were most recently revised on September 15th 2022. The trial requires 120 individuals from two medical centres to take part."

Answered by AI
~41 spots leftby Apr 2025